IN2012DN05888A - - Google Patents

Info

Publication number
IN2012DN05888A
IN2012DN05888A IN5888DEN2012A IN2012DN05888A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A IN 5888DEN2012 A IN5888DEN2012 A IN 5888DEN2012A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A
Authority
IN
India
Prior art keywords
pro
emulsion formulations
taxane
kits
making
Prior art date
Application number
Other languages
English (en)
Inventor
Kiichiro Nabeta
Original Assignee
Teikoku Pharma Usa Inc
Techno Guard Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc, Techno Guard Co Ltd filed Critical Teikoku Pharma Usa Inc
Publication of IN2012DN05888A publication Critical patent/IN2012DN05888A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN5888DEN2012 2010-02-19 2011-02-18 IN2012DN05888A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30631510P 2010-02-19 2010-02-19
PCT/US2011/025418 WO2011103413A2 (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same

Publications (1)

Publication Number Publication Date
IN2012DN05888A true IN2012DN05888A (enrdf_load_stackoverflow) 2015-09-18

Family

ID=44477026

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5888DEN2012 IN2012DN05888A (enrdf_load_stackoverflow) 2010-02-19 2011-02-18

Country Status (9)

Country Link
US (2) US8569357B2 (enrdf_load_stackoverflow)
EP (1) EP2536407A4 (enrdf_load_stackoverflow)
JP (1) JP2013520435A (enrdf_load_stackoverflow)
KR (1) KR20120126072A (enrdf_load_stackoverflow)
CN (1) CN102762202A (enrdf_load_stackoverflow)
AU (1) AU2011217951B2 (enrdf_load_stackoverflow)
IN (1) IN2012DN05888A (enrdf_load_stackoverflow)
TW (1) TWI438009B (enrdf_load_stackoverflow)
WO (1) WO2011103413A2 (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857037B1 (en) * 2012-05-31 2019-06-26 Kinki University Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU673057B2 (en) * 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
JP5005847B2 (ja) * 1997-07-29 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 親油性化合物用の自己乳化性処方
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6281175B1 (en) * 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
DE69917609T2 (de) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao Arzneimittel und deren verwendung
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO1999059550A1 (en) * 1998-05-20 1999-11-25 The Liposome Company, Inc. Novel particulate formulations
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
EP1185301A1 (en) * 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CN100376291C (zh) * 1999-05-27 2008-03-26 阿库斯菲尔公司 多孔药物基质及其制造方法
TW422706B (en) * 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
WO2001025223A1 (en) * 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
JP3448006B2 (ja) * 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
WO2003057128A2 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
ES2273078T3 (es) * 2002-08-21 2007-05-01 Pharmacia Corporation Suspension farmaceutica inyectable en un vial con dos camaras.
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
EP2317978A2 (en) * 2008-07-23 2011-05-11 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
CN101428002A (zh) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 注射用紫杉醇冻干微乳剂及其制备方法

Also Published As

Publication number Publication date
JP2013520435A (ja) 2013-06-06
US20110207803A1 (en) 2011-08-25
WO2011103413A3 (en) 2012-01-12
EP2536407A4 (en) 2013-08-14
AU2011217951B2 (en) 2013-07-11
TW201141538A (en) 2011-12-01
KR20120126072A (ko) 2012-11-20
CN102762202A (zh) 2012-10-31
AU2011217951A1 (en) 2012-07-19
WO2011103413A2 (en) 2011-08-25
US20140088181A1 (en) 2014-03-27
EP2536407A2 (en) 2012-12-26
TWI438009B (zh) 2014-05-21
US8569357B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
WO2012077120A3 (en) Natural formulations
WO2013123114A3 (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2012051210A3 (en) Mesenchymal stem cells and related therapies
GEP201706733B (en) Anti-il-23 antibodies
WO2012099930A3 (en) Flavonol compositions
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
IL226377A0 (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
ZA201401782B (en) Chromobacterium formulations,compositions,metabolites and their uses
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
PH12012502163A1 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
IN2012DN03404A (enrdf_load_stackoverflow)
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2012088222A3 (en) Methods and compositions for producing active vitamin k-dependent proteins
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
IL226174A0 (en) Impulse preparations and methods for their preparation
WO2012051126A3 (en) Anti-inflammatory macrolides
IN2012DN05888A (enrdf_load_stackoverflow)
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
WO2012139074A3 (en) Migrastatins and uses thereof